← Saturday 31 Octobernote 6 of 15
Health researchSat 31 Oct 2026 · 6 of 15

FDA grants accelerated approval for first plasmid DNA immunotherapy, Voceryq, for adult RRP

Verified · 5/5 supported1 cited · 1 min read

The U.S. Food and Drug Administration granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid‑gxfd) to treat adults with recurrent respiratory papillomatosis (RRP) . Voceryq is the first plasmid DNA‑based immunotherapy approved in the United States . RRP is a rare disease caused by human papillomavirus that produces wart‑like growths in the airways . Clinical data showed Voceryq reduces the burden of surgical intervention for RRP patients .

Why it matters. The approval provides a new therapeutic option that can lessen the frequency of surgeries for adults living with RRP .

Earlier on Health research

Fri 30 Oct 2026Study Finds Fruit and Veggie Scraps Are Rich in Dietary FiberMedical Xpress reports that most people routinely discard the peels, skins, stalks and seeds of fruits and vegetables at mealtime. Medical Xpress reports that new research from King's College London suggests these discarded parts could be a valuable source of dietary fiber, offering potential health and environmental benefits. Medical Xpress reports that the study, published in the International Journal of Food Sciences and Nutrition, analyzed 12 common types of fresh produce in the U.K.. Medical Xpress reports that in 10 out of 12 cases, the 'root-to-tip' components such as peels, skins and stalks contained significantly higher levels of dietary fiber than the portions normally eaten. Medical Xpress reports that only 4% of British adults meet the recommended minimum daily intake of 30 g of dietary fiber, highlighting a public health shortfall alongside a food‑waste crisis.Thu 29 Oct 2026Video decision aid boosts advance care planning for seniors with advanced kidney diseaseMedical Xpress reports that a video decision aid increases advance care planning documentation in the electronic health record for older adults with advanced chronic kidney disease. Medical Xpress reports that the study was published in JAMA Internal Medicine to coincide with Kidney Week, the American Society of Nephrology's annual meeting held Oct. 21‑25 in Denver. Medical Xpress reports that the research was led by Angelo E. Volandes, M.D., of Dartmouth Health, and conducted as a multicenter, parallel‑group randomized clinical trial across 12 ambulatory clinics. Medical Xpress reports that the trial enrolled 225 control participants who received usual medical care. Medical Xpress reports that 228 intervention participants viewed a certified video decision aid and created a video declaration stating their treatment preferences.Thu 29 Oct 2026New HS Management Guidelines Issue 37 RecommendationsMedical Xpress reports that evidence‑based recommendations for the management of hidradenitis suppurativa were issued by the American Academy of Dermatology and the Hidradenitis Suppurativa Foundation and published online on Oct. 20 in the Journal of the American Academy of Dermatology. Medical Xpress reports that Haley B. Naik, M.D., and colleagues from the University of California, San Francisco conducted a systematic review that produced 37 evidence‑based recommendations. Medical Xpress reports that the strongly recommended treatments include adalimumab, bimekizumab, infliximab, secukinumab, and routine pain assessment. Medical Xpress reports that conditional recommendations cover topical therapies such as clindamycin, resorcinol and ruxolitinib, systemic antibiotics including oral doxycycline, tetracycline, clindamycin with rifampin and intravenous ertapenem, as well as hormone therapy with spironolactone, short‑term systemic corticosteroids and upadacitinib, plus procedural interventions and tobacco cessation.
Next · Film and TVTV Insider reports on early Season 17 developments for Gold Rush miners →